Decoy Therapeutics Inc. (DCOY)
NASDAQ: DCOY · Real-Time Price · USD
0.9200
-0.0552 (-5.66%)
Nov 16, 2026, 9:56 AM EST - Market open

Decoy Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
0.54----1.84
Revenue Growth
------64.84%
Cost of Revenue
-----8.55
Gross Profit
0.54-----6.71
Selling, General & Admin
5.013.734.965.727.146.1
Research & Development
3.740.370.777.1715.84-
Operating Expenses
8.754.15.7312.8922.986.1
Operating Income
-8.22-4.1-5.73-12.89-22.98-12.81
Interest & Investment Income
0.10.10.160.350.22-
Other Non Operating Income (Expenses)
0.08---0.010.04
EBT Excluding Unusual Items
-8.05-4-5.58-12.54-22.74-12.77
Impairment of Goodwill
-----8.87-
Pretax Income
-16.56-12.52-5.58-12.54-31.61-12.77
Net Income
-16.56-12.52-5.58-12.54-31.61-12.77
Net Income to Common
-16.56-12.52-5.58-12.54-31.61-12.77
Net Income Growth
------
Shares Outstanding (Basic)
100---
Shares Outstanding (Diluted)
100---
Shares Change
486.89%20.93%----
EPS (Basic)
-29.61-129.10-69.54---
EPS (Diluted)
-29.61-129.10-69.54---
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-9.39-4.83-4.53-12.85-17.6-10.2
Free Cash Flow Per Share
-16.78-49.78-56.44---
Gross Margin
100.00%-----
Operating Margin
-1535.69%-----696.27%
Profit Margin
-3095.72%-----693.84%
Free Cash Flow Margin
-1754.53%-----554.29%
EBITDA
-8.17-4.09-5.73-12.88-22.97-12.79
D&A For EBITDA
0.050.0100.010.010.02
EBIT
-8.22-4.1-5.73-12.89-22.98-12.81